There's a line that politicians opposed to embryonic stem cell research have been peddling lately: recent breakthroughs in stem cell technology have now made ethically questionable embryonic stem cell research obsolete and unnecessary. This isn't a new line - for years, opponents of embryonic stem cell research have always claimed that the latest research (whatever it happens to be) has obviated the need for embryonic stem cells.

ZURICH, May 6 /PRNewswire/ --

- Barionet devices allow operators to remotely monitor operations and security threats

Barix AG, a pioneer in IP-based audio, intercom, control, and monitoring, today announced the installation of more than 1,000 Barix Barionet IP control devices to monitor power cabinets and substations throughout Singapore.

SYDNEY, May 6 /PRNewswire/ --

- Problems Getting Email on Your Mobile, Sending Pictures or Browsing the Web? - it's Over!

Configuremyphone.com launches today, offering a solution to the millions of Australians who struggle to manually set-up their mobile phones for services such as email, internet browsing and picture messaging.

One in five Australian mobile users has experienced the disappointment of an error message when trying to send a picture, download a mobile game or use their phone to surf the internet. Even more suffer problems when trying to set-up their phone to access an email account. Many of these errors are caused by incomplete or missing settings on the phone.

BOSTON, May 6 /PRNewswire/ --

- Zendesk to introduce integration with Tactile CRM at June London meetup

Inspiring the help desk 2.0 movement through a focus on enlightened customer support, Zendesk has secured series A venture capital financing from Charles River Ventures. Zendesk's (http://www.zendesk.com/) SaaS (software as a service) help desk system has been providing tender loving customer care to companies since 2007 and has now passed the 1,000 customer mark, including nearly 200 in the UK such as Conde Nast Publications, John Lewis plc and the Environment Agency. The financing will be used to expand operations and painless customer support to organizations worldwide, starting with a new U.S. headquarters in Boston.

COPENHAGEN, May 6 /PRNewswire/ --

- Zendesk's help desk in the cloud brings tender loving customer care to 1,000 organizations

HOUSTON and BARCELONA, Spain, May 6 /PRNewswire/ --

On Tuesday, May 5, 2009, Fractus S.A. of Barcelona, Spain sued cell phone manufacturers Samsung, LG, RIM, Pantech, Kyocera, Palm, HTC, Sharp, UTStarcom, and Sanyo for infringing nine different patents held by Fractus.

Fractus is an early pioneer in developing internal antennas for cellular phones and other industries. Founded in 1999, Fractus set out to meet the challenge of delivering antennas small enough to fit inside a cell phone yet powerful enough to support today's multiband cell phones. Fractus has been, and remains, an active supplier of antennas and has shipped millions of antennas worldwide.

MUMBAI, May 6 /PRNewswire/ -- A Process Training program Developed by Tata Interactive Systems (TIS) was recently short-listed in the Best e-learning program category at the Training Journal (TJ) Awards 2009.

TIS' program to facilitate Micronutrient Initiative (MI) and World Food Programme's (WFP) initiative to eradicate iodine deficiency through structured training on salt quality for salt manufacturers across Africa was short-listed in the Best e-learning program category at the Training Journal (TJ) Awards.

The TJ Awards follow the TJ Conference, which selects the top twelve names from all sections of the learning industry including HR, LD, Diversity, Coaching, Training, and Corporate organizations.

STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. The results showed that a single-day dosing of AXL1717 could be successfully escalated with excellent tolerability. No dose-limiting toxicity was reported. The next part of the trial has now been approved, including a seven-day dosing BID regimen instead of single-day BID treatments. The first patients have already been treated with AXL1717 for seven days.

REHOVOT, Israel, May 6 /PRNewswire/ -- D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA. Recently, D-Pharm also obtained Scientific Advice from the European Medicines Agency (EMEA) on the development strategy for DP-b99 in Europe.

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.